Related Experiment Video
Updated: Aug 6, 2026
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Governing molecular tumor boards: Precision funnel analysis, outcome gap, and a pay-at-result reform framework -
Mauro Iannopollo1, Greta Berti2
1Division of Medical Oncology (SOC), USL Toscana Centro, Pistoia and Pescia Hospitals, Italy.
Purpose:
Molecular Tumor Boards (MTBs) are widely implemented in precision oncology, yet no health system has established a mandatory outcome accountability framework. This article uses Italy's nationally mandated MTB programme, established by Ministerial Decree in 2023 and progressively adopted through formal regional acts (15 of 21 regions and autonomous provinces by 2024), as a case study of a governance gap affecting MTB programmes across health systems.
Methods:
Synthesis of published evidence across 34 studies and 12,176 patients, Italian institutional series (IEO Milan, IRE Rome), the NCI-MATCH trial, and ESMO 2024 NGS recommendations.
Results:
Cumulative attrition in the MTB pathway reduces real-world clinical benefit to approximately 8 of every 100 patients discussed. Four structural mechanisms drive this: absence of mandatory ESCAT-based pre-triage; conflation of genomic alterations with actionable targets (the driver/passenger fallacy); absent outcome registries; and failure to evaluate whether MTB network architecture is volumetrically justified. Cost per patient with documented benefit is estimated at €26,000-66,000.
Conclusions:
Four mutually reinforcing reforms are proposed: mandatory ESCAT I/II pre-discussion triage; a national outcome registry linked to six-month therapeutic outcome; a pay-at-result basket trial in which industry provides matched therapy free of charge with reimbursement contingent on verified clinical benefit; and a structured pilot to evaluate MTB model adequacy as molecular profiling evolves. Each reform is grounded in operational precedents: the UK Cancer Drugs Fund, the French Accès Précoce mechanism, and the German MASTER trial network.
Insights
Precision oncology
Area of Science:
- Oncology
- Genomics
- Health Systems Research
Background:
- Molecular Tumor Boards (MTBs) are crucial in precision oncology.
- No health system has a mandatory outcome accountability framework for MTBs.
- Italy's national MTB program (established 2023) serves as a case study for governance gaps.
Purpose of the Study:
- To analyze the governance gap in Italy's national Molecular Tumor Board (MTB) program.
- To identify structural mechanisms causing attrition in the MTB pathway.
- To propose reforms for improving MTB program effectiveness and accountability.
Main Methods:
- Synthesized evidence from 34 studies (12,176 patients).
- Included Italian institutional data (IEO Milan, IRE Rome).
- Incorporated NCI-MATCH trial data and ESMO 2024 NGS recommendations.
Main Results:
- Significant attrition in the MTB pathway yields clinical benefit for only ~8% of patients discussed.
- Key issues include lack of pre-triage, conflation of genomic alterations with actionable targets, absent outcome registries, and unverified network architecture.
- Estimated cost per patient with documented benefit ranges from €26,000 to €66,000.
Conclusions:
- Propose four reforms: mandatory ESCAT triage, national outcome registry, pay-at-result basket trials, and pilot evaluation of MTB model adequacy.
- Reforms are based on successful international precedents (UK Cancer Drugs Fund, French Accès Précoce, German MASTER trial).
- These reforms aim to enhance accountability and clinical benefit within precision oncology programs.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:21Cancer Survival Analysis